BRCA1 and hyperinsulinemic hypoglycemia, familial, 4: HR-mediated DNA repair deficiency, typified by BRCA1 mutations, has the strongest association with efficacy of platinum-based therapies in TNBC and is a major determinant of which patients receive platinum regimens (70, 71).